Epidemiological study, pathologic evaluation and prognostic factors of colorectal mucinous adenocarcinoma VS non mucinous (About a series of 196 patients)


Amira Arfaoui Toumi
Lilia Kriaa Ben Mahmoud
Meriem Khiari
Ahlem Lahmer
Lasaad Gharbi
Monia Dhraïef
Tahar khalfallah
Sabeh Regaya Mzabi
Saadia Bouraoui1


Background: Colorectal carcinoma is one of the main causes of cancer death in the worldwide with a decrease survival rate in relationship with a later diagnosis of advanced disease.
Aims: This study highlights the particular epidemiological, clinicopathological and immunohistochemical colorectal cancer profile. Indeed, our results differ markedly from that reported in the literature.
Methods: We underwent a retro and prospective study interesting 196 patients with colorectal carcinoma diagnosed in the pathological and cytological laboratory of Mongi Slim Hospital (Tunisia). Age at diagnosis, mode of presentation, sex, tumour location, macroscopic and histological features, TNM and Astler Coller stage were assessed and evaluated.
Results: we report here a particular epidemiological pattern which is characterised by younger age of the patients, equally distribution between men and women, predominant sporadic carcinomas and preponderance of rectosigmoid location. The poorer degree of differentiation and mucinous subtype are correlated with an advanced stage. It is also correlated with more frequent vascular embols, neural invasion and metastatic nodes. Furthermore, immunohistochemical analysis of galectin-3 showed a significantdifference between mucinous and non mucinous adenocarcinoma.
Conclusion: Based on the presented data, the epidemiological pattern and the anatomic distribution especially in the rectosigmoid region suggest diet and lifestyle to be primordial risk factors of colorectal tumorigenesis.


Epidemiology, Colorectal cancer, Mucinous adenocarcinoma, Immunohistochemistry, Galectin-3



  1. Hassan Brim, Pooneh Mokarram, Fakhraddin Naghibalhossaini et al. Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer 2008; 7:68.
  2. Ferlay J, Bray F, Pisani P, Parkin DM, GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC cancer Base No.5, Version 2.0. Lyon: International Agency for Research on Cancer; 2004.
  3. Thiravud Khuhaprema and Petcharin Srivatanakul. Colon and Rectum Cancer in Thailand: An Overview. Jpn J Clin Oncol 2008;38:237-243.
  4. Peter Boyle, J S Langman. Epidemiology. ABC of colorectal cancer. Clinical review. BMJ 2000;321:805-808.
  5. Cotran R.S, Kumar.V, Robbins. L. Pathologie : Bases morphologiques et physio-pathologiques des maladies Paris : Edition Française 1996 :964-84.
  6. Resistre des cancers Nord-Tunisie (1995-1998). Ministre de la santé publique. Secrétariat d'état à la recherche scientifique et de la technologie. Unité de recherche en épidémiologie des cancers en Tunisie.
  7. Wenbo Du, Ph.D, James T.L, Jeannette Lee et al. Incidence and survival of mucinous adenocarcinoma of the colorectum : Apopulation-Based study from an Asian country. Dis Colon Rectum 2004; 47:78-85.
  8. Carriquiry LA, Pineyro A. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis Colon Rectum 1999;42:921-9.
  9. Lasser P, Mankarios H, Elias D, et al. Étude pronostique uni- et multifactorielle de 400 adénocarcinomes rectaux réséqués. J Chir (Paris) 1993; 130:57-65.
  10. Horn A, Dahl O, Morild I. venous and neural invasion as predictors of recurrence in recta adenocarcinoma. Dis Colon Rectum 1991;34:798-804.
  11. N. Arfa, I. Hamdani, L. Gharbi, et al. Survie et facteurs pronostiques des adénocarcinomes colorectaux : étude analytique uni- et multifactorielle de 150 cas. Annales de chirurgie 2006;131:104-11
  12. Néel JC, Lasser P, Letessier E et al. Traitement chirurgical des cancers coliques après 75 ans. Étude d'une série de 240 patients. Chirurgie 1999;124:670-4.
  13. Kanemitsu Y, Kato T, Hirai T et al. Survival after curative resection for mucinous adenocarcinoma of the colorectum. Dis Colon Rectum 2003;46:160-7.
  14. Malassagne B, Valleur P, Serra J, et al. Relationship of apical lymph node involvement to survival in resected colon carcinoma. Dis Colon Rectum 1993;36:645-53.
  15. Elliot J. Coops, Sharon L. Manne, Neal J. Meropol and David S. Weinberg. Multiple behaviour risk factors for colorectal cancer and screening status. Cancer Epidemiol Biomarkers Prev 2007;16:510-6.
  16. Akahani S, Nangia-Makker P, Inohara H, et al. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997;57:5272-6.
  17. Danguy A, Camby I, Kiss R. Galectins and cancer. Biochim Biophys Acta 2000;19:285-93.
  18. Davidson PJ, Davis MJ, Patterson RJ, et al. Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 2002;12:329-37.
  19. Lin H-M, Pestell RG, Raz A, Kim HRC. Galectin-3 enhances cyclin D1 promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene 2002;21:8001-10.